NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=114502&from=3 CLASS PERIO ...

Core Insights - Edwards Lifesciences Corporation is focused on long-term growth and innovation in structural heart therapies, particularly in TAVR and TMTT [1][2] - The company anticipates strong sales growth in 2025, projecting an increase of 8% to 10% driven by advancements in its technologies [2][5] Growth Drivers - TAVR is expected to generate sales of $4.1 to $4.4 billion in 2025, with a constant currency growth rate of 5% to 7% [4] - TMTT is forecasted to grow by 50% to 60% in 2025, with projected sales of $500 to $530 million [4] - New technologies like the EVOQUE tricuspid valve and PASCAL system are crucial for growth, alongside anticipated regulatory approvals for SAPIEN M3 [4] - The company aims for an average annual sales growth of 10% and double-digit EPS growth starting in 2026, driven by its expanding range of structural heart therapies [4] Financial Outlook - Edwards projects total sales for 2025 to be between $5.6 billion and $6 billion, slightly below the consensus of $5.91 billion [5] - Adjusted earnings per share are expected to be in the range of $2.40 to $2.50, compared to the consensus of $2.44, with gross profit margins of 78% to 79% [5] Market Performance - Edwards Lifesciences' stock increased by 4.21%, reaching $73.15 [6]

SAN FRANCISCO , Dec. 04, 2024 (GLOBE NEWSWIRE) -- Investors in Edwards Lifesciences Corporation (NYSE: EW) contend that the medical device giant misled them about the growth prospects of its core product, the Transcatheter Aortic Valve Replacement (TAVR) platform. A class action lawsuit has been filed, accusing the company of securities fraud and claiming that executives painted a misleading picture of TAVR's future growth potential. Hagens Berman urges Edwards Lifesciences Corporation investors who suffere ...

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Edwards Lifesciences Corporation ("Edwards Lifesciences " or the "Company") (NYSE: EW) investors of a class action representing investors that bought securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"). Edwards Lifesciences investors have until December 13, 2024 to file a lead plaintiff motion. Investors are en ...

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

SAN DIEGO, Dec. 2, 2024 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, all dates inclusive (the "Class Period"), have until Friday, December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit.  Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences class action lawsuit ch ...

NEW YORK, Nov. 30, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

NEW YORK, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

Edwards Lifesciences (EW) has announced one-year, real-world data on its SAPIEN 3 Ultra RESILIA valve at the PCR London Valves 2024. These data add to the extensive body of evidence on the company’s SAPIEN valve platform, backed by multiple years of follow-up and more than 10 years of clinical experience with the RESILIA tissue.The latest development should bolster Edwards’ Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart groups. The findings were simultaneously published in the J ...